Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HLA-DR ligands from BLCLs 9022 and 9087

ABSTRACT: HLA-DR-bound peptides eluted from B-lymphoblastoid cell lines 9022 and 9087.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Cell Suspension Culture

SUBMITTER: Sri Ramarathinam

LAB HEAD: Anthony Purcell

PROVIDER: PXD017682 | Pride | 2020-03-11

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	9022DR-all_sprot_v2016_12.group	Other
	9022DR-all_sprot_v2016_12.mgf	Mgf
	9087-DR-all_sprot_v2016_12.group	Other
	9087-DR-all_sprot_v2016_12.mgf	Mgf
	9087A12-3DR1.wiff	Wiff

Items per page:

1 - 5 of 91

Similar Datasets

Identification of HLA-B*57:01-restricted endogenous and HIV epitopes

Project description:A novel modified HLA-B*57:01-restricted epitope was identified in one of the reversed-phase fractions following immunoaffinity purification of HLA-peptide complexes from C1R cells expressing HIV envelope protein. Also includes six immunopeptidome datasets from several B57 and env transfected cell lysates.

2018-02-19 | PXD004471 | Pride

Trans-splicing of class I HLA bound peptides diversifies the immunopeptidome

Project description:The diversity of peptides displayed by class I HLA plays an essential role in T cell immunity. The peptide repertoire is extended by various post-translational modifications, including cis-splicing of peptides from the same protein. Here, we have applied a novel bioinformatic workflow and demonstrate that spliced-peptides are also generated through trans-splicing (fusion of peptide segments from distinct antigens) and their abundance challenges current models of proteasomal-splicing that predict cis-splicing as the most probable outcome. These trans-spliced peptides display canonical HLA binding motif sequence features. These results highlight the unanticipated diversity of the immunopeptidome and have important implications for autoimmunity, vaccine design and immunotherapy.

2018-10-16 | PXD009660 | Pride

Trans-splicing of class I HLA bound peptides diversifies the immunopeptidome

2021-12-06 | PXD017922 | Pride

Influenza-derived peptide presentation by HLA-A*24:02

Project description:Identification of influenza virus-derived peptides presented by Human Leukocyte Antigen (HLA) molecules of the C1R (Class I reduced) B-lymphoblastoid cell line, transfected with the HLA class I allele HLA-A*24:02, after influenza infection.

2021-04-08 | PXD020292 | Pride

HLA-DQ8 Immunopeptidomics, Type 1 Diabetes

Project description:In this project we will investigate the peptides present by HLA-DQ8. We will identify linear, spliced and PTM peptides from one cell line.

2021-07-07 | PXD019466 | Pride

Impact of abacavir and abacavir analogues on HLA-B*57:01 peptide presentation

Project description:Characterisation of peptide ligands of the Major histocompatibility class (MHC) I allele, HLA-B*57:01, expressed in the C1R (Class I reduced) B-lymphoblastoid cell line, after exposure to the anti-retroviral abacavir or abacavir analogues.

2019-10-03 | PXD015398 | Pride

C1R.B*58:01 MHC class I immunopeptidome LC-MSMS

Project description:Characterisation of peptide ligands of Major histocompatibility class (MHC) I isolated by immunoaffinity purification from the C1R (Class I reduced) B-lymphoblastoid cell line, transfected with the MHC class I allele HLA-B*58:01.

2018-10-24 | PXD008572 | Pride

The RNA-binding proteins SRP14 and HMGB3 control HIV-1 Tat mRNA processing and translation during HIV-1 latency

Project description:HIV-1 Tat protein is essential for virus production. RNA-binding proteins that facilitate Tat production may be absent or downregulated in resting CD4+ T-cells, the main reservoir of latent HIV. In this study, we examined the role of Tat RNA-binding proteins on the expression of Tat and control of latent and productive infection.

2021-06-14 | PXD025782 | Pride

Immunopeptidome of an acute myeloid leukemia cell line THP1

Project description:We report the use of complementary peptide antigen enrichment and comprehensive mass spectrometric acquisition strategies to provide in-depth immunopeptidome data for AML cell line THP1

2020-05-13 | PXD015039 | Pride

Sampling from proteome to HLA-DR ligandome

Project description:Comprehensive analysis of the complex nature of the Human Leukocyte Antigen (HLA) class II ligandome is of utmost importance to understand the basis for CD4+ T cell mediated immunity and tolerance. Here, we implemented important improvements in the analysis of the repertoire of HLA-DR-presented peptides, using hybrid mass spectrometry-based peptide fragmentation techniques on a ligandome sample isolated from matured human monocyte-derived dendritic cells (DC). The reported data set constitutes nearly 14 thousand unique high-confident peptides, i.e. the largest single inventory of human DC derived HLA-DR ligands to date. From a technical viewpoint the most prominent finding is that no single peptide fragmentation technique could elucidate the majority of HLA-DR ligands, due to the wide range of physical chemical properties displayed by the HLA-DR ligandome. Our in-depth profiling allowed us to reveal a strikingly modest correlation between the abundance levels of surface-presented peptides and the cellular expression of their source proteins. Important selective sieving from the sampled proteome to the ligandome, was evidenced by specificity in the sequences of the core regions both at their N- and C- termini, hence not only reflecting binding motifs but also dominant protease activity associated to the endolysosomal compartments. Moreover, we demonstrate that the HLA-DR ligandome reflects a surface representation of cell-compartments specific for biological events linked to the maturation of monocytes into antigen presenting cells. Our results present new perspectives into the complex nature of the HLA class II system and will aid future immunological studies in characterizing the full breadth of potential CD4+ T cell epitopes relevant in health and disease.

2016-01-25 | PXD002951 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data